
Axcella Health Inc. – NASDAQ:AXLA
Axcella Health stock price monthly change
Axcella Health stock price quarterly change
Axcella Health stock price yearly change
Axcella Health key metrics
Market Cap | N/A |
Enterprise value | 7.84M |
P/E | -0.28 |
EV/Sales | N/A |
EV/EBITDA | -0.06 |
Price/Sales | N/A |
Price/Book | 5.48 |
PEG ratio | -0.02 |
EPS | -0.89 |
Revenue | N/A |
EBITDA | -35.43M |
Income | -50.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAxcella Health stock price history
Axcella Health stock forecast
Axcella Health financial statements
Sep 2022 | 0 | -18.58M | |
---|---|---|---|
Dec 2022 | 0 | -24.25M | |
Mar 2023 | 0 | -3.76M | |
Jun 2023 | 0 | -3.41M |
2025 | 0 | -15.94M |
---|
Analysts Price target
Financials & Ratios estimates
Sep 2022 | 30788000 | 38.34M | 124.53% |
---|---|---|---|
Dec 2022 | 18927000 | 14.76M | 78% |
Mar 2023 | 12765000 | 12.03M | 94.3% |
Jun 2023 | 9282000 | 11.54M | 124.33% |
Sep 2022 | -18.52M | 10.17M | -301K |
---|---|---|---|
Dec 2022 | -15.53M | -19K | 7.27M |
Mar 2023 | -5.10M | 525K | -27K |
Jun 2023 | -3.65M | 0 | 13.32B |
Axcella Health alternative data
Aug 2023 | 11 |
---|---|
Sep 2023 | 11 |
Oct 2023 | 11 |
Nov 2023 | 11 |
Dec 2023 | 11 |
Jan 2024 | 11 |
Feb 2024 | 11 |
Mar 2024 | 11 |
Apr 2024 | 11 |
May 2024 | 11 |
Jun 2024 | 11 |
Jul 2024 | 11 |
Axcella Health other data
Period | Buy | Sel |
---|---|---|
Jun 2022 | 0 | 590 |
Sep 2022 | 0 | 547 |
Oct 2022 | 14042296 | 16000 |
Feb 2023 | 0 | 5221 |
Mar 2023 | 0 | 679 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | KOZIEL MARGARET officer: Chief Medical Officer | Common Stock | 679 | $0.58 | $394 | ||
Sale | FEHLNER PAUL officer: SVP & Chief Legal Offi.. | Common Stock | 5,221 | $0.66 | $3,446 | ||
Sale | HINSHAW WILLIAM director, officer.. | Common Stock | 16,000 | $1.56 | $25,024 | ||
Purchase | SOCIETE DES PRODUITS NESTLE S.A. 10 percent owner | Common Stock | 3,658,536 | $1.64 | $5,999,999 | ||
Purchase | FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent owner | Common Stock | 2,743,902 | $1.64 | $4,499,999 | ||
Purchase | FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent owner | Common Stock | 3,048,780 | $1.64 | $4,999,999 | ||
Purchase | FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent owner | Common Stock | 919,111 | $1.64 | $1,507,342 | ||
Purchase | FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent owner | Common Stock | 914,634 | $1.64 | $1,500,000 | ||
Purchase | FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC 10 percent owner | Common Stock | 2,757,333 | $1.64 | $4,522,026 | ||
Sale | KOZIEL MARGARET officer: Chief Medical Officer | Common Stock | 547 | $2.52 | $1,378 |
Patent |
---|
Grant Filling date: 19 Jun 2019 Issue date: 12 Apr 2022 |
Grant Filling date: 19 Dec 2017 Issue date: 28 Sep 2021 |
Application Filling date: 8 Jun 2021 Issue date: 23 Sep 2021 |
Application Filling date: 2 Mar 2021 Issue date: 23 Sep 2021 |
Application Filling date: 19 Jun 2019 Issue date: 9 Sep 2021 |
Application COMPOSITIONS AND METHODS FOR THE REDUCTION OR TREATMENT OF INSULIN RESISTANCE AND METABOLIC CONDITIONS Filling date: 19 Jun 2019 Issue date: 9 Sep 2021 |
Application Filling date: 19 Jun 2019 Issue date: 26 Aug 2021 |
Grant Filling date: 19 Jun 2019 Issue date: 13 Jul 2021 |
Application Filling date: 9 Oct 2020 Issue date: 6 May 2021 |
Grant Filling date: 7 Feb 2020 Issue date: 13 Apr 2021 |
Quarter | Transcript |
---|---|
Q3 2022 1 Nov 2022 | Q3 2022 Earnings Call Transcript |
Q4 2021 30 Mar 2022 | Q4 2021 Earnings Call Transcript |
Q2 2021 31 Jul 2021 | Q2 2021 Earnings Call Transcript |
Q4 2020 17 Mar 2021 | Q4 2020 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. William R. Hinshaw Jr. (1969) Pres, Chief Executive Officer & Director | $812,050 |
Mr. Laurent Chardonnet (1965) Consultant | $576,060 |
-
When is Axcella Health's next earnings date?
Unfortunately, Axcella Health's (AXLA) next earnings date is currently unknown.
-
Does Axcella Health pay dividends?
No, Axcella Health does not pay dividends.
-
What is Axcella Health's stock symbol?
Axcella Health Inc. is traded on the NASDAQ under the ticker symbol "AXLA".
-
What is Axcella Health's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Axcella Health?
Shares of Axcella Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Axcella Health's key executives?
Axcella Health's management team includes the following people:
- Mr. William R. Hinshaw Jr. Pres, Chief Executive Officer & Director(age: 56, pay: $812,050)
- Mr. Laurent Chardonnet Consultant(age: 60, pay: $576,060)
-
How many employees does Axcella Health have?
As Jul 2024, Axcella Health employs 11 workers.
-
When Axcella Health went public?
Axcella Health Inc. is publicly traded company for more then 6 years since IPO on 9 May 2019.
-
What is Axcella Health's official website?
The official website for Axcella Health is axcellahealth.com.
-
Where are Axcella Health's headquarters?
Axcella Health is headquartered at 840 Memorial Drive, Cambridge, MA.
-
How can i contact Axcella Health?
Axcella Health's mailing address is 840 Memorial Drive, Cambridge, MA and company can be reached via phone at 857 320 2200.
Axcella Health company profile:

Axcella Health Inc.
axcellahealth.comNASDAQ
11
Biotechnology
Healthcare
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Cambridge, MA 02139
CIK: 0001633070
ISIN: US05454B2043
CUSIP: 05454B105